Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Hoffmann-La Roche
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A randomized, open-label phase III Intergroup study: Effect of adding Bevacizumab to cross over fluoropyrimidine based chemotherapy (CTx) in patients with metastatic colorectal cancer and disease progression under first-line standard CTx / Bevacizumab combination
To assess Overall survival (OS)
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 6 ans
Étude GO28399 : étude visant à fournir un accès continu au vemurafénib à des patients ayant une tumeur maligne et porteurs de la mutation BRAFV600 ayant précédemment été inclus et traités dans un protocole antérieur portant sur le vemurafénib. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
La mutation BRAF V600 est présente dans certains types de cancer, y compris le mélanome, le cancer colorectal et le cancer du poumon non à petites cellules. Elle peut augmenter la capacité de croissan...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A Study to Evaluate the Effectiveness and Safety of Prophylactic Emicizumab Versus no Prophylaxis in Haemophilia A Patients Without Inhibitors
•To evaluate the efficacy of prophylactic emicizumab (1.5 mg/kg/week or 3 mg/kg/2weeks) compared with no prophylaxis in patients with haemophilia A without FVIII inhibitors on the basis of the number ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
International study assessing two different vismodegib regiments in people with multiple basal cell carcinomas
To assess the relative reduction from baseline (%) in the number of clinically evident BCCs at a defined time point in two different vismodegib regiments.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 5 ans
GO27878 : Essai de phase 1 randomisé, évaluant la tolérance et la dose optimale à administrer du GDC-0199 associé à une chimiothérapie de type CHOP (cyclophosphamide, doxorubicine, vincristine, prednisone) combiné soit au rituximab, soit au obinutuzumab, chez des patients ayant un lymphome non hodgkinien à cellules B et un lymphome diffus à grandes cellules B. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance du GDC-0199 en association avec une chimiothérapie combiné soit à du rituximab, soit à de l’obinutuzumab, chez des patients ayant un ...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A Phase Ib/II, open-label study of the safety, tolerability, and efficacy of trastuzumab-MCC-DM1 in combination with pertuzumab administered intravenously to patients with HER2-positive locally advanced or metastatic breast cancer who have progressed while receiving prior therapy
• To characterize the safety and tolerability of the combination of T-DM1 and pertuzumab administered every 3 weeks to patients with HER2-positive locally advanced or metastatic breast cancer who have...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study To Evaluate The Efficacy and Safety of Two Doses of Ocrelizumab in Subjects With WHO or ISN Class III or IV Nephritis Due To Systemic Lupus Erythematosus
To investigate the ability of the ocrelizumab regimen in combination with standard of care treatment (SOC) to induce a complete or partial renal response, as assessed by renal function, urinary sedime...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 5 ans
A Study to Evaluate the Safety and Efficacy of RO7123520 as Adjunct Treatment in Patients With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to TNF-α Inhibitors
•To assess the safety, tolerability and efficacy of RO7123520 as adjunctive treatment with Methotrexate (MTX) and anti- Tumor necrosis factor-α (TNF-α) therapy in patients with moderately to severely ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F.Hoffmann-La Roche
Update Il y a 5 ans
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus Infection
To evaluate the safety, tolerability, and effect on virologicalresponse of a 12 and 24-week duration of RO5190591 incombination with Pegasys and Copegus compared to thecombination of Pegasys and Copeg...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 5 ans
Étude ML39349 : étude de phase 2 évaluant l’efficacité et la tolérance de l’alectinib chez des patients ayant un cancer du poumon non à petites cellules avec réarrangement ALK. [essai clos aux inclusions]
Le cancer du poumon se développe à partir de cellules situées dans le poumon et qui se sont multipliées de manière anormale pour former une masse ou une tumeur. Le cancer du poumon non à petites cellu...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Previous
19
20
21
22
23
24
25
26
27
28
Next